Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Citation: Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW.: Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. Drug Metab Dispos, Volume 40 (11), 2012
Authors: Bowers GD, Castellino S, Culp AG, Dobbins RL, Humphreys JE, Hussey EK, Kapur A, O'Connor Semmes RL, Polli JW., Reese MJ, Sigafoos JF, Tao W, Wagner DS
Journal: Drug Metab Dispos
Year: 2012
DOI: 10.1124/dmd.112.047258
PubMed: 22851617
Machine-readable: REST API RDF

Publication